EU Regulators Lift Temporary COVID-19 Measures But Resources Remain An Issue
Executive Summary
The European Medicines Agency said that while the temporary measures that were introduced to cope with the peak impact of the COVID-19 pandemic were no longer required, “resourcing within the entire European medicines regulatory network remains a challenge.”
You may also be interested in...
Bigger Trials, More RWE Needed for Future Crisis Response, Say EU Regulators
A report from the EU medicines regulatory network looks at what was done well in the response to the COVID-19 pandemic, and what needs to be improved if we are to be better prepared next time.
EMA Seeks New Transparency Managers As Clinical Data Publication Policy Restarts
The transparency department at the European Medicines Agency is hiring two heads to manage its clinical data publication policy and access to documents service.
No More Pandemic-Related Regulatory Flexibilities For Companies In EU
Regulatory flexibilities that were introduced to address constraints that marketing authorization holders were potentially facing because of the COVID-19 pandemic are being stopped or phased out.